Company intelligence / Profile preview

Naogen Pharma

Saint-Herblain/Nantes, Francenaogen-pharma.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

Naogen Pharma develops and manufactures radiopharmaceutical products for nuclear medicine, focusing on a Strontium/Rubidium‑82 generator and injector system used for PET imaging. The company aims to improve detection of myocardial ischemia and has positioned itself as a key player in the European market. It received GMP manufacturing authorization in France in 2023. Its lead product targets functional molecular imaging for cardiology with potential expansion into oncology applications. The company was founded by Jean-François Chatal, a recognized expert in nuclear medicine.

Therapeutic areas: OncologyCardiovascular
Modalities: Radiopharmaceuticals (notably PET-rubidium 82 generator/injector)
Industry: Medical Imaging

Drug pipeline

1 asset

strontium-82/rubidium-82 generator

Commercial

Indications: Myocardial ischemia detection

Beyond the preview

Go deeper on Naogen Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naogen Pharma.

Explore the full profile